Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

Elective Nodal Irradiation Attenuates the Combinatorial Efficacy of Stereotactic Radiation Therapy and Immunotherapy.

Marciscano AE, Ghasemzadeh A, Nirschl TR, Theodros D, Kochel CM, Francica BJ, Muroyama Y, Anders RA, Sharabi AB, Velarde E, Mao W, Chaudhary KR, Chaimowitz MG, Wong J, Selby MJ, Thudium KB, Korman AJ, Ulmert D, Thorek DLJ, DeWeese TL, Drake CG.

Clin Cancer Res. 2018 Jun 13. doi: 10.1158/1078-0432.CCR-17-3427. [Epub ahead of print]

PMID:
29898992
2.

The impact of age on radium-223 distribution and an evaluation of molecular imaging surrogates.

Jiang W, Ulmert D, Simons BW, Abou DS, Thorek DLJ.

Nucl Med Biol. 2018 Jul - Aug;62-63:1-8. doi: 10.1016/j.nucmedbio.2018.05.003. Epub 2018 May 8.

3.

Feed-forward alpha particle radiotherapy ablates androgen receptor-addicted prostate cancer.

McDevitt MR, Thorek DLJ, Hashimoto T, Gondo T, Veach DR, Sharma SK, Kalidindi TM, Abou DS, Watson PA, Beattie BJ, Timmermand OV, Strand SE, Lewis JS, Scardino PT, Scher HI, Lilja H, Larson SM, Ulmert D.

Nat Commun. 2018 Apr 24;9(1):1629. doi: 10.1038/s41467-018-04107-w.

4.

Twenty-year Risk of Prostate Cancer Death by Midlife Prostate-specific Antigen and a Panel of Four Kallikrein Markers in a Large Population-based Cohort of Healthy Men.

Sjoberg DD, Vickers AJ, Assel M, Dahlin A, Poon BY, Ulmert D, Lilja H.

Eur Urol. 2018 Jun;73(6):941-948. doi: 10.1016/j.eururo.2018.02.016. Epub 2018 Mar 5.

PMID:
29519548
5.

Long-term prediction of prostate cancer diagnosis and death using PSA and obesity related anthropometrics at early middle age: data from the malmö preventive project.

Assel MJ, Gerdtsson A, Thorek DLJ, Carlsson SV, Malm J, Scardino PT, Vickers A, Lilja H, Ulmert D.

Oncotarget. 2017 Dec 5;9(5):5778-5785. doi: 10.18632/oncotarget.22981. eCollection 2018 Jan 19.

6.

Androgen Deprivation Therapy Potentiates the Efficacy of Vascular Targeted Photodynamic Therapy of Prostate Cancer Xenografts.

Kim K, Watson PA, Lebdai S, Jebiwott S, Somma AJ, La Rosa S, Mehta D, Murray KS, Lilja H, Ulmert D, Monette S, Scherz A, Coleman JA.

Clin Cancer Res. 2018 May 15;24(10):2408-2416. doi: 10.1158/1078-0432.CCR-17-3474. Epub 2018 Feb 20.

PMID:
29463549
7.

Association Between Lead Time and Prostate Cancer Grade: Evidence of Grade Progression from Long-term Follow-up of Large Population-based Cohorts Not Subject to Prostate-specific Antigen Screening.

Assel M, Dahlin A, Ulmert D, Bergh A, Stattin P, Lilja H, Vickers AJ.

Eur Urol. 2018 Jun;73(6):961-967. doi: 10.1016/j.eururo.2017.10.004. Epub 2017 Oct 21.

PMID:
29066048
8.

In vivo immuno-targeting of an extracellular epitope of membrane bound preferentially expressed antigen in melanoma (PRAME).

Pankov D, Sjöström L, Kalidindi T, Lee SG, Sjöström K, Gardner R, McDevitt MR, O'Reilly R, Thorek DLJ, Larson SM, Veach D, Ulmert D.

Oncotarget. 2017 Jul 26;8(39):65917-65931. doi: 10.18632/oncotarget.19579. eCollection 2017 Sep 12.

9.

Carbon nanotubes exhibit fibrillar pharmacology in primates.

Alidori S, Thorek DLJ, Beattie BJ, Ulmert D, Almeida BA, Monette S, Scheinberg DA, McDevitt MR.

PLoS One. 2017 Aug 28;12(8):e0183902. doi: 10.1371/journal.pone.0183902. eCollection 2017.

10.

Internalization of secreted antigen-targeted antibodies by the neonatal Fc receptor for precision imaging of the androgen receptor axis.

Thorek DL, Watson PA, Lee SG, Ku AT, Bournazos S, Braun K, Kim K, Sjöström K, Doran MG, Lamminmäki U, Santos E, Veach D, Turkekul M, Casey E, Lewis JS, Abou DS, van Voss MR, Scardino PT, Strand SE, Alpaugh ML, Scher HI, Lilja H, Larson SM, Ulmert D.

Sci Transl Med. 2016 Nov 30;8(367):367ra167.

11.

Kinase Regulation of Human MHC Class I Molecule Expression on Cancer Cells.

Brea EJ, Oh CY, Manchado E, Budhu S, Gejman RS, Mo G, Mondello P, Han JE, Jarvis CA, Ulmert D, Xiang Q, Chang AY, Garippa RJ, Merghoub T, Wolchok JD, Rosen N, Lowe SW, Scheinberg DA.

Cancer Immunol Res. 2016 Nov;4(11):936-947. Epub 2016 Sep 28.

12.

Screening for Prostate Cancer Starting at Age 50-54 Years. A Population-based Cohort Study.

Carlsson S, Assel M, Ulmert D, Gerdtsson A, Hugosson J, Vickers A, Lilja H.

Eur Urol. 2017 Jan;71(1):46-52. doi: 10.1016/j.eururo.2016.03.026. Epub 2016 Apr 13.

13.

Radioimmunotherapy of prostate cancer targeting human kallikrein-related peptidase 2.

Vilhelmsson Timmermand O, Larsson E, Ulmert D, Tran TA, Strand S.

EJNMMI Res. 2016 Dec;6(1):27. doi: 10.1186/s13550-016-0181-z. Epub 2016 Mar 17.

14.

Whole-Body and Microenvironmental Localization of Radium-223 in Naïve and Mouse Models of Prostate Cancer Metastasis.

Abou DS, Ulmert D, Doucet M, Hobbs RF, Riddle RC, Thorek DL.

J Natl Cancer Inst. 2015 Dec 18;108(5). pii: djv380. doi: 10.1093/jnci/djv380. Print 2016 May.

15.

Vitamin D, PTH, and calcium and tumor aggressiveness in prostate cancer: a prospective nested case-control study.

Brändstedt J, Almquist M, Ulmert D, Manjer J, Malm J.

Cancer Causes Control. 2016 Jan;27(1):69-80. doi: 10.1007/s10552-015-0684-3. Epub 2015 Oct 30.

PMID:
26518197
16.

Contemporary approaches for imaging skeletal metastasis.

Ulmert D, Solnes L, Thorek DLj.

Bone Res. 2015 Jul 14;3:15024. doi: 10.1038/boneres.2015.24. eCollection 2015. Review.

17.

Reverse-Contrast Imaging and Targeted Radiation Therapy of Advanced Pancreatic Cancer Models.

Thorek DL, Kramer RM, Chen Q, Jeong J, Lupu ME, Lee AM, Moynahan ME, Lowery M, Ulmert D, Zanzonico P, Deasy JO, Humm JL, Russell J.

Int J Radiat Oncol Biol Phys. 2015 Oct 1;93(2):444-53. doi: 10.1016/j.ijrobp.2015.06.001. Epub 2015 Jun 9.

18.

Preclinical imaging of kallikrein-related peptidase 2 (hK2) in prostate cancer with a (111)In-radiolabelled monoclonal antibody, 11B6.

Timmermand OV, Ulmert D, Evans-Axelsson S, Pettersson K, Bjartell A, Lilja H, Strand SE, Tran TA.

EJNMMI Res. 2014 Dec;4(1):51. doi: 10.1186/s13550-014-0051-5. Epub 2014 Sep 19.

19.

Anthropometric Measures at Multiple Times Throughout Life and Prostate Cancer Diagnosis, Metastasis, and Death.

Gerdtsson A, Poon JB, Thorek DL, Mucci LA, Evans MJ, Scardino P, Abrahamsson PA, Nilsson P, Manjer J, Bjartell A, Malm J, Vickers A, Freedland SJ, Lilja H, Ulmert D.

Eur Urol. 2015 Dec;68(6):1076-82. doi: 10.1016/j.eururo.2015.03.017. Epub 2015 Mar 18.

20.

Radiolabeled antibodies in prostate cancer: a case study showing the effect of host immunity on antibody bio-distribution.

Vilhelmsson-Timmermand O, Santos E, Thorek DL, Evans-Axelsson S, Bjartell A, Lilja H, Larson SM, Strand SE, Tran TA, Ulmert D.

Nucl Med Biol. 2015 Apr;42(4):375-80. doi: 10.1016/j.nucmedbio.2014.12.012. Epub 2014 Dec 23.

21.

Cabozantinib resolves bone scans in tumor-naïve mice harboring skeletal injuries.

Doran MG, Spratt DE, Wongvipat J, Ulmert D, Carver BS, Sawyers CL, Evans MJ.

Mol Imaging. 2014;13. doi: 10.2310/7290.2014.00026.

22.

Influence of blood prostate specific antigen levels at age 60 on benefits and harms of prostate cancer screening: population based cohort study.

Carlsson S, Assel M, Sjoberg D, Ulmert D, Hugosson J, Lilja H, Vickers A.

BMJ. 2014 Mar 28;348:g2296. doi: 10.1136/bmj.g2296.

23.

Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen.

Vickers AJ, Sjoberg DD, Ulmert D, Vertosick E, Roobol MJ, Thompson I, Heijnsdijk EA, De Koning H, Atoria-Swartz C, Scardino PT, Lilja H.

BMC Med. 2014 Feb 11;12:26. doi: 10.1186/1741-7015-12-26.

24.

Non-invasive mapping of deep-tissue lymph nodes in live animals using a multimodal PET/MRI nanoparticle.

Thorek DL, Ulmert D, Diop NF, Lupu ME, Doran MG, Huang R, Abou DS, Larson SM, Grimm J.

Nat Commun. 2014;5:3097. doi: 10.1038/ncomms4097.

25.

REST mediates androgen receptor actions on gene repression and predicts early recurrence of prostate cancer.

Svensson C, Ceder J, Iglesias-Gato D, Chuan YC, Pang ST, Bjartell A, Martinez RM, Bott L, Helczynski L, Ulmert D, Wang Y, Niu Y, Collins C, Flores-Morales A.

Nucleic Acids Res. 2014 Jan;42(2):999-1015. doi: 10.1093/nar/gkt921. Epub 2013 Oct 24.

26.

N-acetyltransferase 2 phenotype, occupation, and bladder cancer risk: results from the EPIC cohort.

Pesch B, Gawrych K, Rabstein S, Weiss T, Casjens S, Rihs HP, Ding H, Angerer J, Illig T, Klopp N, Bueno-de-Mesquita B, Ros MM, Kaaks R, Chang-Claude J, Roswall N, Tjønneland A, Overvad K, Clavel-Chapelon F, Boutron-Ruault MC, Dossus L, Boeing H, Weikert S, Trichopoulos D, Palli D, Sieri S, Tumino R, Panico S, Quirós JR, González C, Sánchez MJ, Dorronsoro M, Navarro C, Barricarte A, Ljungberg B, Johansson M, Ulmert D, Ehrnström R, Khaw KT, Wareham N, Key TJ, Ferrari P, Romieu I, Riboli E, Brüning T, Vineis P.

Cancer Epidemiol Biomarkers Prev. 2013 Nov;22(11):2055-65. doi: 10.1158/1055-9965.EPI-13-0119-T. Epub 2013 Oct 3.

27.

Prostate-specific kallikrein-related peptidases and their relation to prostate cancer biology and detection. Established relevance and emerging roles.

Thorek DL, Evans MJ, Carlsson SV, Ulmert D, Lilja H.

Thromb Haemost. 2013 Sep;110(3):484-92. doi: 10.1160/TH13-04-0275. Epub 2013 Aug 1. Review.

28.

Prostate cancer imaging trends after a nationwide effort to discourage inappropriate prostate cancer imaging.

Makarov DV, Loeb S, Ulmert D, Drevin L, Lambe M, Stattin P.

J Natl Cancer Inst. 2013 Sep 4;105(17):1306-13. doi: 10.1093/jnci/djt175. Epub 2013 Jul 23.

29.

Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study.

Vickers AJ, Ulmert D, Sjoberg DD, Bennette CJ, Björk T, Gerdtsson A, Manjer J, Nilsson PM, Dahlin A, Bjartell A, Scardino PT, Lilja H.

BMJ. 2013 Apr 15;346:f2023. doi: 10.1136/bmj.f2023.

30.

Low expression of SHP-2 is associated with less favorable prostate cancer outcomes.

Tassidis H, Brokken LJ, Jirström K, Bjartell A, Ulmert D, Härkönen P, Wingren AG.

Tumour Biol. 2013 Apr;34(2):637-42. doi: 10.1007/s13277-012-0590-1. Epub 2012 Nov 29.

PMID:
23192641
31.

Smoking and the risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition.

Rohrmann S, Linseisen J, Allen N, Bueno-de-Mesquita HB, Johnsen NF, Tjønneland A, Overvad K, Kaaks R, Teucher B, Boeing H, Pischon T, Lagiou P, Trichopoulou A, Trichopoulos D, Palli D, Krogh V, Tumino R, Ricceri F, Argüelles Suárez MV, Agudo A, Sánchez MJ, Chirlaque MD, Barricarte A, Larrañaga N, Boshuizen H, van Kranen HJ, Stattin P, Johansson M, Bjartell A, Ulmert D, Khaw KT, Wareham NJ, Ferrari P, Romieux I, Gunter MJ, Riboli E, Key TJ.

Br J Cancer. 2013 Feb 19;108(3):708-14. doi: 10.1038/bjc.2012.520. Epub 2012 Nov 20.

32.

Prospective study on metabolic factors and risk of prostate cancer.

Häggström C, Stocks T, Ulmert D, Bjørge T, Ulmer H, Hallmans G, Manjer J, Engeland A, Nagel G, Almqvist M, Selmer R, Concin H, Tretli S, Jonsson H, Stattin P.

Cancer. 2012 Dec 15;118(24):6199-206. doi: 10.1002/cncr.27677. Epub 2012 Oct 22.

33.

Fruit and vegetable consumption and risk of aggressive and non-aggressive urothelial cell carcinomas in the European Prospective Investigation into Cancer and Nutrition.

Ros MM, Bueno-de-Mesquita HB, Kampman E, Büchner FL, Aben KK, Egevad L, Overvad K, Tjønneland A, Roswall N, Clavel-Chapelon F, Boutron-Ruault MC, Morois S, Kaaks R, Teucher B, Weikert S, von Ruesten A, Trichopoulou A, Naska A, Benetou V, Saieva C, Pala V, Ricceri F, Tumino R, Mattiello A, Peeters PH, van Gils CH, Gram IT, Engeset D, Chirlaque MD, Ardanazx E, Rodríguez L, Amanio P, Gonzalez CA, Sánchez MJ, Ulmert D, Ernström R, Ljungberg B, Allen NE, Key TJ, Khaw KT, Wareham N, Slimani N, Romieu I, Kiemeney LA, Riboli E.

Eur J Cancer. 2012 Nov;48(17):3267-77. doi: 10.1016/j.ejca.2012.05.026. Epub 2012 Aug 3.

PMID:
22863148
34.
35.

Imaging androgen receptor signaling with a radiotracer targeting free prostate-specific antigen.

Ulmert D, Evans MJ, Holland JP, Rice SL, Wongvipat J, Pettersson K, Abrahamsson PA, Scardino PT, Larson SM, Lilja H, Lewis JS, Sawyers CL.

Cancer Discov. 2012 Apr;2(4):320-7. doi: 10.1158/2159-8290.CD-11-0316. Epub 2012 Mar 31.

36.

Targeting free prostate-specific antigen for in vivo imaging of prostate cancer using a monoclonal antibody specific for unique epitopes accessible on free prostate-specific antigen alone.

Evans-Axelsson S, Ulmert D, Örbom A, Peterson P, Nilsson O, Wennerberg J, Strand J, Wingårdh K, Olsson T, Hagman Z, Tolmachev V, Bjartell A, Lilja H, Strand SE.

Cancer Biother Radiopharm. 2012 May;27(4):243-51. doi: 10.1089/cbr.2011.1088. Epub 2012 Apr 10.

37.

A novel automated platform for quantifying the extent of skeletal tumour involvement in prostate cancer patients using the Bone Scan Index.

Ulmert D, Kaboteh R, Fox JJ, Savage C, Evans MJ, Lilja H, Abrahamsson PA, Björk T, Gerdtsson A, Bjartell A, Gjertsson P, Höglund P, Lomsky M, Ohlsson M, Richter J, Sadik M, Morris MJ, Scher HI, Sjöstrand K, Yu A, Suurküla M, Edenbrandt L, Larson SM.

Eur Urol. 2012 Jul;62(1):78-84. doi: 10.1016/j.eururo.2012.01.037. Epub 2012 Jan 27.

38.

Evaluation of multiple risk-associated single nucleotide polymorphisms versus prostate-specific antigen at baseline to predict prostate cancer in unscreened men.

Klein RJ, Hallden C, Gupta A, Savage CJ, Dahlin A, Bjartell A, Manjer J, Scardino PT, Ulmert D, Wallström P, Vickers AJ, Lilja H.

Eur Urol. 2012 Mar;61(3):471-7. doi: 10.1016/j.eururo.2011.10.047. Epub 2011 Nov 7.

39.

Elevated level of Wnt5a protein in localized prostate cancer tissue is associated with better outcome.

Syed Khaja AS, Helczynski L, Edsjö A, Ehrnström R, Lindgren A, Ulmert D, Andersson T, Bjartell A.

PLoS One. 2011;6(10):e26539. doi: 10.1371/journal.pone.0026539. Epub 2011 Oct 24.

40.

High RBM3 expression in prostate cancer independently predicts a reduced risk of biochemical recurrence and disease progression.

Jonsson L, Gaber A, Ulmert D, Uhlén M, Bjartell A, Jirström K.

Diagn Pathol. 2011 Sep 28;6:91. doi: 10.1186/1746-1596-6-91.

41.

miR-34c is downregulated in prostate cancer and exerts tumor suppressive functions.

Hagman Z, Larne O, Edsjö A, Bjartell A, Ehrnström RA, Ulmert D, Lilja H, Ceder Y.

Int J Cancer. 2010 Dec 15;127(12):2768-76. doi: 10.1002/ijc.25269.

42.

Red meat, dietary nitrosamines, and heme iron and risk of bladder cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC).

Jakszyn P, González CA, Luján-Barroso L, Ros MM, Bueno-de-Mesquita HB, Roswall N, Tjønneland AM, Büchner FL, Egevad L, Overvad K, Raaschou-Nielsen O, Clavel-Chapelon F, Boutron-Ruault MC, Touillaud MS, Chang-Claude J, Allen NE, Kiemeney LA, Key TJ, Kaaks R, Boeing H, Weikert S, Trichopoulou A, Oikonomou E, Zylis D, Palli D, Berrino F, Vineis P, Tumino R, Mattiello A, Peeters PH, Parr CL, Gram IT, Skeie G, Sánchez MJ, Larrañaga N, Ardanaz E, Navarro C, Rodríguez L, Ulmert D, Ehrnström R, Hallmans G, Ljungberg B, Roddam AW, Bingham SA, Khaw KT, Slimani N, Boffetta PA, Jenab M, Mouw T, Michaud DS, Riboli E.

Cancer Epidemiol Biomarkers Prev. 2011 Mar;20(3):555-9. doi: 10.1158/1055-9965.EPI-10-0971. Epub 2011 Jan 14.

43.

A panel of kallikrein marker predicts prostate cancer in a large, population-based cohort followed for 15 years without screening.

Vickers AJ, Gupta A, Savage CJ, Pettersson K, Dahlin A, Bjartell A, Manjer J, Scardino PT, Ulmert D, Lilja H.

Cancer Epidemiol Biomarkers Prev. 2011 Feb;20(2):255-61. doi: 10.1158/1055-9965.EPI-10-1003. Epub 2010 Dec 8.

44.

PCA3 as a diagnostic marker for prostate cancer: a validation study on a Swedish patient population.

Nyberg M, Ulmert D, Lindgren A, Lindström U, Abrahamsson PA, Bjartell A.

Scand J Urol Nephrol. 2010 Dec;44(6):378-83. doi: 10.3109/00365599.2010.521187. Epub 2010 Oct 21.

PMID:
20961267
45.

Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50.

Lilja H, Cronin AM, Dahlin A, Manjer J, Nilsson PM, Eastham JA, Bjartell AS, Scardino PT, Ulmert D, Vickers AJ.

Cancer. 2011 Mar 15;117(6):1210-9. doi: 10.1002/cncr.25568. Epub 2010 Oct 19.

46.

Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study.

Vickers AJ, Cronin AM, Björk T, Manjer J, Nilsson PM, Dahlin A, Bjartell A, Scardino PT, Ulmert D, Lilja H.

BMJ. 2010 Sep 14;341:c4521. doi: 10.1136/bmj.c4521.

47.

Male infertility and prostate cancer risk: a nested case-control study.

Ruhayel Y, Giwercman A, Ulmert D, Rylander L, Bjartell A, Manjer J, Berglund G, Giwercman YL.

Cancer Causes Control. 2010 Oct;21(10):1635-43. doi: 10.1007/s10552-010-9592-8. Epub 2010 Jun 4.

PMID:
20524053
48.

Empirical estimates of the lead time distribution for prostate cancer based on two independent representative cohorts of men not subject to prostate-specific antigen screening.

Savage CJ, Lilja H, Cronin AM, Ulmert D, Vickers AJ.

Cancer Epidemiol Biomarkers Prev. 2010 May;19(5):1201-7. doi: 10.1158/1055-9965.EPI-09-1251. Epub 2010 Apr 20.

49.

Immunohistochemical detection of tyrosine phosphatase SHP-1 predicts outcome after radical prostatectomy for localized prostate cancer.

Tassidis H, Brokken LJ, Jirström K, Ehrnström R, Pontén F, Ulmert D, Bjartell A, Härkönen P, Wingren AG.

Int J Cancer. 2010 May 15;126(10):2296-307. doi: 10.1002/ijc.24917.

50.

Prostate kallikrein markers in diagnosis, risk stratification and prognosis.

Ulmert D, O'Brien MF, Bjartell AS, Lilja H.

Nat Rev Urol. 2009 Jul;6(7):384-91. doi: 10.1038/nrurol.2009.123. Review.

Supplemental Content

Loading ...
Support Center